ARTICLE | Company News
Lupin gets newly approved drug in Symbiomix deal
October 13, 2017 7:48 PM UTC
Lupin Ltd. (NSE:LUPIN; BSE:500257) said it acquired anti-infectives company Symbiomix Therapeutics LLC (Newark, N.J.). The deal gives the Indian pharma rights to Solosec secnidazole, which FDA approved last month to treat bacterial vaginosis.
Symbiomix shareholders received $50 million upfront, and are eligible for another $100 million in milestones, plus contingent payments...